Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis

Shah, Shailja C.; Tepler, Adam; Chung, Cecilia P.; Suárez, Giovanni; Peek, Richard M.; Hung, Adriana M.; Roumie, Christianne L.; Narula, Neeraj

doi:10.1053/j.gastro.2021.07.043

Cited by 23 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…pylori are rising, which gives rise to a high recrudescence of H. pylori infection . Herein, only CLR was used and enzyme-responsive ePDA shells of mSZ-Clr@ePDA NPs could protect CLR from gastric acid damage.…”

Section: Resultsmentioning

confidence: 92%

“…More pressingly, the reported prevalence of metronidazole resistance reaches as high as 90%, and those of CLR and amoxicillin resistance to H. pylori are rising, which gives rise to a high recrudescence of H. pylori infection. 1 Herein, only CLR was used and enzyme-responsive ePDA shells of mSZ-Clr@ePDA NPs could protect CLR from gastric acid damage. US-propelled motion promoted NP adsorption onto gastric walls and penetration into mucus, followed by H. pylori-triggered CLR release.…”

Section: 4mentioning

confidence: 99%

“…The reported prevalence of CLR resistance is approximately 50% and has reached alarming levels due to drastically high recrudescence of H. pylori infection. 1 The short residence time and rapid degradation by gastric acid cause insufficient retention of antibiotics in the gastric mucosa, and the use of broad spectrum antibiotics leads to undesirable removal of intestinal symbiotic bacteria, which disturbs the balance related to metabolic processes. 2 In addition, H. pylori essentially colonize inside the gastric mucus, and the biofilm formation on the epithelial cell layer has been confirmed by endoscopic biopsy examination.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ultrasound-Activated Persistent Luminescence Imaging and Bacteria-Triggered Drug Release for Helicobacter pylori Infection Theranostics

Zhou

Zhang

Qiu

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is recognized as a pathogenic factor related to gastrointestinal diseases and gastric cancer. The theranostics of H. pylori infection is confronted with challenges from colonization on the epithelial cell layer and formation of bacterial biofilms, which prevent interactions with imaging probes and antimicrobial agents. Herein, theranostic nanoparticles (NPs) are developed with ultrasonication (US)-propelled motion and US-excited persistent luminescence for precise imaging and efficient eradication of H. pylori. Mechanoluminescent SrAl 2 O 4 :Eu 2+ (SAOE) and persistently luminescent ZnGa 2 O 4 :Cr 3+ (ZGC) nanodots (NDs) were in situ deposited on mesoporous silica NPs to prepare mSZ NPs. mSZ-Clr@ ePDA NPs were fabricated through surface adsorption of clarithromycin (CLR) and then coating with enzyme-responsive polydopamine layers (ePDA). US-activated SAOE NDs generate emissions to excite ZGC NDs for persistent emission of near-infrared (NIR) afterglows, but they are quenched by the ePDA coatings. The disintegration of ePDA layers by bacterial phospholipase rapidly restores NIR emissions for imaging of H. pylori biofilms and simultaneously triggers the CLR release. US-driven motion promotes NP penetration and CLR delivery across mucus into biofilms, leading to full destruction of the biofilm matrix and embedded bacteria. In an H. pyloriinfection model, mSZ-Clr@ePDA/US treatment enhances the retention of NPs in the stomach and penetration across mucus and accumulation on the epithelial layer, and the US-activated persistent emission provides a real-time diagnosis of H. pylori infection without autofluorescence. The US-propelled accumulation of mSZ-Clr@ePDA NPs and local release of CLR in biofilms significantly eliminate bacterial burdens in gastric tissues at a lower dose of antibiotics. Thus, this study offers a feasible strategy to activate persistent emission in deep tissues and provides a potential theranostic solution for non-invasive imaging and efficient removal of H. pylori infection.

show abstract

Section: Resultsmentioning

confidence: 92%

Section: 4mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultrasound-Activated Persistent Luminescence Imaging and Bacteria-Triggered Drug Release for Helicobacter pylori Infection Theranostics

Zhou

Zhang

Qiu

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Antibiotic resistance is one of multiple factors implicated in H. pylori treatment failure, along with comorbidities such as diabetes mellitus, cigarette smoking, CYP2C19 metabolizer genotype, and non-adherence to therapy; however, it remains the most significant [74][75][76][77]. Genotypic methods for detecting antibiotic resistance hold promise for identifying those at risk of treatment failure but are not yet sufficiently sensitive nor universally available.…”

Section: Discussionmentioning

confidence: 99%

Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients

et al. 2022

View full text Add to dashboard Cite

Helicobacter pylori is a common gastric pathogen associated with multiple clinical syndromes, including cancer. Eradication rates of H. pylori remain suboptimal despite the progress made in the past few decades in improving treatment strategies. The low eradication rates are mainly driven by antibiotic resistance of H. pylori. Non-invasive molecular testing to identify patients with antibiotic-resistant H. pylori represents a promising therapeutic avenue, however this technology currently remains limited by availability, costs, and lack of robust validation. Moreover, there is insufficient evidence to demonstrate that resistance-testing-based treatment approaches are superior to appropriately designed empiric strategies. Consensus guidelines recommend use of proven locally effective regimens; however, eradication data are inconsistently generated in several regions of the world. In this review, we describe several clinical factors associated with increased rates of antibiotic resistant H. pylori, including history of previous antibiotic exposure, increasing age, female gender, ethnicity/race, extent of alcohol use, and non-ulcer dyspepsia. Assessment of these factors may aid the clinician in choosing the most appropriate empiric treatment strategy for each patient. Future study should aim to identify locally effective therapies and further explore the clinical factors associated with antibiotic resistance.

show abstract

“…Патогенетические механизмы дистропических процессов изучены крайне недостаточно [33]. В первую очередь это относится к генетическим аспектам дистропий [34].…”

Section: перспективы индивидуализированной эрадикационной терапии Hel...unclassified

Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra

Симаненков

Алексеенко²

2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The article is devoted to debatable aspects of Helicobacter pylori eradication therapy. The eradication cancer-preventive effects are considered. A negative comorbidity between H. pylori infection and such diseases as gastroesophageal reflux disease, inflammatory bowel disease and bronchial asthma has been described. The perspectives of populational, individualized and personalized strategies for H. pylori eradication therapy assessment are given. Recommendations for individualized H. pylori eradication strategy implementation in practical healthcare are proposed.

show abstract

Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis

Cited by 23 publications

References 51 publications

Ultrasound-Activated Persistent Luminescence Imaging and Bacteria-Triggered Drug Release for Helicobacter pylori Infection Theranostics

Ultrasound-Activated Persistent Luminescence Imaging and Bacteria-Triggered Drug Release for Helicobacter pylori Infection Theranostics

Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients

Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra

Contact Info

Product

Resources

About